Discovery and Preclinical Antitumor Efficacy Evaluations of LY32262 and LY33169

@article{Corbett2004DiscoveryAP,
  title={Discovery and Preclinical Antitumor Efficacy Evaluations of LY32262 and LY33169},
  author={Thomas H. Corbett and Kathryn White and Lisa A. Polin and Juiwanna Kushner and Jennifer Paluch and Chuan Shih and Cora Sue Grossman},
  journal={Investigational New Drugs},
  year={2004},
  volume={21},
  pages={33-45}
}
The discoveries of a new antitumor agent (LY32262) (N-[2,4-dichlorobenzoyl]phenylsulfonamide) and a close analog (LY33169) are described. For this discovery, a disk-diffusion-soft-agar-colony-formation-assay was used to screen a portion of the Eli Lilly inventory, with the evaluation of each agent against normal cells, leukemic cells and several solid tumors, including a multidrug-resistant solid tumor (with marked selective cytotoxicity for Colon-38 and Human-Colon-15/MDR compared to normal… Expand
Novel acyl sulfonamide LY573636-sodium: effect on hematopoietic malignant cells.
TLDR
The study of the anti-tumor properties of LY573636 against a variety of human hematopoietic malignancies, including AML, B-ALL, large B-cell and mantle cell lymphoma cell lines and its effect on cell proliferation, apoptosis and differentiation is determined. Expand
Tasisulam Sodium, an Antitumor Agent That Inhibits Mitotic Progression and Induces Vascular Normalization
TLDR
Data show that tasisulam has a unique, dual-faceted mechanism of action involving mitotic catastrophe and antiangiogenesis, a phenotype distinct from conventional chemotherapies and published anticancer agents. Expand
Metronidazole acid acyl sulfonamide: a novel class of anticancer agents and potential EGFR tyrosine kinase inhibitors.
TLDR
A new series of metronidazole acid acyl sulfonamide derivatives and a newseries of phenylacetyl benzenesulfonamide derivative and their anticancer activities were evaluated as potential EGFR and HER-2 kinase inhibitors and compound 12 displayed the most potent inhibitory activity. Expand
Overcoming PLK1 inhibitor resistance by targeting mevalonate pathway to impair AXL-TWIST axis in colorectal cancer.
TLDR
Targeting the mevalonate pathway contributes to re-sensitizing BI2536-resistant cells in vitro and in vivo, raising as a new strategy for the clinical management of PLK1 inhibitors. Expand
Assessing Cytotoxic Treatment Effects in Preclinical Tumor Xenograft Models
TLDR
A nonparametric bootstrap percentile interval of the LCK is proposed for cytotoxic treatment effect and Monte Carlo simulations are conducted to study the coverage probabilities of the proposed interval for small samples. Expand
Reduction of breast tumor burden in mice by a prenylated flavonoid, Artonin E
TLDR
With the capacity to reduce in vivo tumour growth, Artonin E has a great prospect to be developed into an anticancer agent. Expand
Loss of SLCO1B3 drives taxane resistance in prostate cancer
TLDR
The SLCO1B3 determines intracellular concentrations of docetaxel and cabazitaxe and consequently influences taxane efficacy and may drive taxane resistance in prostate cancer. Expand
Synthesis, Molecular Structure, Metabolic Stability and QSAR Studies of a Novel Series of Anticancer N-Acylbenzenesulfonamides
TLDR
Quantitative structure-activity relationship studies on the cytotoxic activity of N-acylsulfonamides toward MCF-7, HCT-116 and HeLa were performed by using topological, ring and charge descriptors based on the stepwise multiple linear regression technique (MLR). Expand
Synthesis and structure-activity relationship of 4-azaheterocycle benzenesulfonamide derivatives as new microtubule-targeting agents.
TLDR
A series of 1-sulfonyl indolines was synthesized and evaluated for antiproliferative activity, and the most potent compounds 9 a and 9 e showed significant cytotoxicity against four human cancer cell lines. Expand
Interval approach to assessing antitumor activity for tumor xenograft studies.
TLDR
An adjusted area-under-the-curve (aAUC) ratio is proposed to quantify tumor growth inhibition and a nonparametric bootstrap t-interval of the aAUC ratio is also proposed for assessing the significance of the antitumor activity of the agents. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 36 REFERENCES
Antitumor efficacy of PD115934 (NSC 366140) against solid tumors of mice.
TLDR
It was determined that PD115934 was a schedule category III agent, i.e., a schedule-independent agent with peak plasma level toxicity, and the main toxicity encountered with infusional therapy was myelosuppression. Expand
Preclinical efficacy of thioxanthone SR271425 against transplanted solid tumors of mouse and human origin
A highly active and broadly active thioxanthone has been identified: N-[[1-[[2-(Diethylamino)ethyl]amino]-7-methoxy-9-oxo-9H-thioxanthen-4-yl] methylformamide (SR271425, BCN326862, WIN71425). InExpand
Preclinical antitumor efficacy of analogs of XK469: sodium-(2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]propionate
TLDR
Assure® had no selective cytotoxicity for solid tumors in the disk-assay, and was devoid of antitumor activity, while the analog XK469 is in clinical development. Expand
Toxicity and anticancer activity of a new triazine antifolate (NSC 127755).
TLDR
A new triazine folate antagonist was highly active against four transplantable colon adenocarcinomas and the Dunning murine ovarian tumor M5076 and treatment schedule studies indicated that a prolonged time of exposure provided optimum antitumor activity for the compound. Expand
Discovery of Solid Tumor Active Agents Using a Soft-Agar-Colony-Formation Disk-Diffusion-Assay
TLDR
The history of antitumor drug discovery has essentially been the use of two lymphocytic leukemias of mice as selection funnels through which all agents needed to pass in order to advance toward clinical development, and it is thus not surprising that agents in the clinic are highly active against these tumor systems. Expand
Discovery of cryptophycin-1 and BCN-183577: Examples of strategies and problems in the detection of antitumor activity in mice
TLDR
A flexible in vivo testing protocol is implemented, where the tumor model is dictated by in vitro cellular sensitivity; drug route by water solubility (with water soluble agents injected intravenously); dosage decrement by drug supply, dose-schedule by toxicities encountered, etc. Expand
Myeloid leukemia C-1498 as a screen for cancer chemotherapeutic agents.
TLDR
Comparative screening of fermentation filtrates against C1498, Sarcoma 180, and leukemia L1210 indicated specificity on the part of C 1498 since the “overlap” rate ( response to the same fermentation) with S180 and L 1210 was less than 8%. Expand
Treatment of human prostate tumors PC-3 and TSU-PR1 with standard and investigational agents in SCID mice
TLDR
Both the PC-3 and the TSU-PR1 prostate tumor models were found to be satisfactory for chemotherapeutic investigations in ICR-SCID mice and activity was determined by the ability of the SCID mice to tolerate meaningful dosages of the agents. Expand
Establishment of cross-resistance profiles for new agents.
TLDR
The cross-resistance profiles of drug-resistant murine tumors to treatment with new drugs going into phase I-II trials should provide useful guides for patient selection for those trials, as well as indicating likely biochemical mechanism of action of new drugs with promising anticancer activity. Expand
Response of human lung tumor xenografts to treatment with a somatostatin analogue (Somatuline).
TLDR
Somatuline administered as a perilesional infusion effectively inhibited xenograft growth inducing prolonged remissions, suggesting antimitogenic activity rather than cytocidal and suggesting the feasibility of long term maintenance therapy with a resultant extended survival. Expand
...
1
2
3
4
...